Orion Oyj (HEL:ORNBV)

Market Cap	6.89B
Revenue (ttm)	1.54B
Net Income (ttm)	329.90M
Shares Out	140.50M
EPS (ttm)	2.35
PE Ratio	20.90
Forward PE	19.45
Dividend	1.64 (3.34%)
Ex-Dividend Date	Oct 15, 2025

Volume	163,586
Average Volume	269,415
Open	49.20
Previous Close	49.34
Day's Range	48.50 - 49.38
52-Week Range	31.86 - 57.70
Beta	0.43
RSI	39.45
Earnings Date	Apr 23, 2025

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 3,880
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: ORNBV

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.